Team

Leadership

miR Scientific has gathered leading minds across highly-specialized areas of expertise including biological research, biostatistics, information systems, patient care, business development and operations. Under the leadership of CEO Sam Salman, the team has harnessed their collective knowledge and abilities to develop one of the most impactful solutions in the field of cancer management.

  • Sam co-founded miR Scientific in 2014. Sam is a serial entrepreneur and a renowned executive who throughout his career held senior executive and board level positions developing game-changing technologies and companies across industries, including Biotech (president – Errant Gene Therapeutics), Art Authentication (CEO – Provenire Authentication), Aquaculture (Chairman – Greenfins Global) and Financial Services (Mission Markets Inc., a pioneering financial services firm focused on impact and sustainability markets.). Sam attended the American University of Paris in France and Macalester College in St. Paul, MN. He is a member of the Board of Trustees and Board of Selectors of the Jefferson Awards for Public Service.
    Sam Salman
    Sam Salman
    CEO & Chairman
  • Sam co-founded miR Scientific in 2014. Sam is a serial entrepreneur and a renowned executive who throughout his career held senior executive and board level positions developing game-changing technologies and companies across industries, including Biotech (president – Errant Gene Therapeutics), Art Authentication (CEO – Provenire Authentication), Aquaculture (Chairman – Greenfins Global) and Financial Services (Mission Markets Inc., a pioneering financial services firm focused on impact and sustainability markets.). Sam attended the American University of Paris in France and Macalester College in St. Paul, MN. He is a member of the Board of Trustees and Board of Selectors of the Jefferson Awards for Public Service.
  • Dr. Tenniswood co-founded miR Scientific in 2014. Prior to that, Dr. Tenniswood served as the director of the Cancer Research Center at the University at Albany and Empire Innovations Professor of biomedical sciences at the School of Public Health. His lab specializes in developing therapies for hard-to-treat hormone dependent cancers, particularly castration-resistant prostate cancer (CRPC) and triple negative breast cancers. The lab uses a variety of high throughput, high content methodologies, including mRNA and miRNA based transcriptomics to understand the biology that leads to tumor progression and drug resistance.
    Dr. Martin Tenniswood Ph.D.
    Dr. Martin Tenniswood Ph.D.
    Co-Founder & Chief Scientific Officer
  • Dr. Tenniswood co-founded miR Scientific in 2014. Prior to that, Dr. Tenniswood served as the director of the Cancer Research Center at the University at Albany and Empire Innovations Professor of biomedical sciences at the School of Public Health. His lab specializes in developing therapies for hard-to-treat hormone dependent cancers, particularly castration-resistant prostate cancer (CRPC) and triple negative breast cancers. The lab uses a variety of high throughput, high content methodologies, including mRNA and miRNA based transcriptomics to understand the biology that leads to tumor progression and drug resistance.
  • Rob co-founded miR Scientific in 2014. Rob is instrumental in strategic development, operations and business development in Canada. He advises start-ups and often judges business plan competitions. Rob obtained his BA and MBA from the University of Notre Dame and studied Entrepreneurship at the Judge Business School at the University of Cambridge.
    Robert Tenniswood
    Robert Tenniswood
    Co-Founder, Chief Operating Officer & President
  • Rob co-founded miR Scientific in 2014. Rob is instrumental in strategic development, operations and business development in Canada. He advises start-ups and often judges business plan competitions. Rob obtained his BA and MBA from the University of Notre Dame and studied Entrepreneurship at the Judge Business School at the University of Cambridge.
  • Dr. DiRienzo serves as Chair, Department of Epidemiology and Biostatistics SUNY Associate Professor of Biostatistics, Department of Epidemiology and Biostatistics, School of Public Health University at Albany. His research focus is the theory and practice of non-parametric and semiparametric statistical methods for model selection in longitudinal studies with missing data; clinical trials; high-dimensional data; survival analysis. Dr. DiRienzo earned his Ph.D. in Mathematics/Statistics & Biometry/Statistics at University at Albany, SUNY and his Postdoctoral Research Fellowship Department of Biostatistics at Harvard University.
    Dr. Gregory DiRienzo, Ph.D.
    Dr. Gregory DiRienzo, Ph.D.
    Director of Biostatistics
  • Dr. DiRienzo serves as Chair, Department of Epidemiology and Biostatistics SUNY Associate Professor of Biostatistics, Department of Epidemiology and Biostatistics, School of Public Health University at Albany. His research focus is the theory and practice of non-parametric and semiparametric statistical methods for model selection in longitudinal studies with missing data; clinical trials; high-dimensional data; survival analysis. Dr. DiRienzo earned his Ph.D. in Mathematics/Statistics & Biometry/Statistics at University at Albany, SUNY and his Postdoctoral Research Fellowship Department of Biostatistics at Harvard University.
  • Dr. Klotz is the past Chief of Urology at Sunnybrook Health Sciences Centre and Professor of Surgery at the University of Toronto. He holds the Sunnybrook Chair of Prostate Cancer Research, is the Chairman of the World Uro-Oncology Federation, and past president of the Urological Research Society and the Canadian Urological Association. He was the founder and is chairman of the Canadian Urology Research Consortium (CURC). Dr. Klotz obtained his medical degree from the University of Toronto and completed his residency at the University of Toronto Gallie Program in Surgery. He was a fellow at Memorial Sloan Kettering Cancer Centre in New York in uro-oncology. Dr. Klotz is a widely published uro-oncologist with over 350 publications and 6 books. His main research interest has been prostate cancer. He is the Associate Editor of the Journal of Urology responsible for Prostate Cancer. He serves on the boards of many medical/scientific organizations and journals, including the SUO, Prostate Cancer Canada, the journals Prostate Cancer and Prostatic Diseases, Brazilian Journal of Urology, Italian Journal of Urology, and World Journal of Urology. Dr. Klotz was awarded the Queen’s Jubilee Medal for meritorious public service in 2012, and the University of Toronto Department of Surgery Lister Prize and the Society of Urologic Oncology Medal in 2013. He received the Harold Warwick Award from the Canadian Cancer Society for "outstanding contributions to cancer control" in 2014. He received the Order of Canada in 2015 and the Richard Williams Award from the AUA in 2016. He received the Dean’s Lifetime Achievement Award from the University of Toronto in 2017.
    Dr. Laurence Klotz, MD, FRCSC, CM
    Dr. Laurence Klotz, MD, FRCSC, CM
    Chief Medical Officer
  • Dr. Klotz is the past Chief of Urology at Sunnybrook Health Sciences Centre and Professor of Surgery at the University of Toronto. He holds the Sunnybrook Chair of Prostate Cancer Research, is the Chairman of the World Uro-Oncology Federation, and past president of the Urological Research Society and the Canadian Urological Association. He was the founder and is chairman of the Canadian Urology Research Consortium (CURC). Dr. Klotz obtained his medical degree from the University of Toronto and completed his residency at the University of Toronto Gallie Program in Surgery. He was a fellow at Memorial Sloan Kettering Cancer Centre in New York in uro-oncology. Dr. Klotz is a widely published uro-oncologist with over 350 publications and 6 books. His main research interest has been prostate cancer. He is the Associate Editor of the Journal of Urology responsible for Prostate Cancer. He serves on the boards of many medical/scientific organizations and journals, including the SUO, Prostate Cancer Canada, the journals Prostate Cancer and Prostatic Diseases, Brazilian Journal of Urology, Italian Journal of Urology, and World Journal of Urology. Dr. Klotz was awarded the Queen’s Jubilee Medal for meritorious public service in 2012, and the University of Toronto Department of Surgery Lister Prize and the Society of Urologic Oncology Medal in 2013. He received the Harold Warwick Award from the Canadian Cancer Society for "outstanding contributions to cancer control" in 2014. He received the Order of Canada in 2015 and the Richard Williams Award from the AUA in 2016. He received the Dean’s Lifetime Achievement Award from the University of Toronto in 2017.
  • Dr. Wang joined miR Scientific as the company’s first employee. She has been instrumental in the development of several innovations key to miR Scientific’s breakthrough approach to cancer management. Dr. Wang is listed as an inventor on several patents,and continues to develop intellectual property for miR Scientific at a breakneck pace. Dr. Wang holds a bachelor’s degree from Queen’s University (Kingston, ON) and a Ph.D from the University at Albany.
    Dr. Wei-Lin “Winnie” Wang, Ph.D
    Dr. Wei-Lin “Winnie” Wang, Ph.D
    Research Director
  • Dr. Wang joined miR Scientific as the company’s first employee. She has been instrumental in the development of several innovations key to miR Scientific’s breakthrough approach to cancer management. Dr. Wang is listed as an inventor on several patents,and continues to develop intellectual property for miR Scientific at a breakneck pace. Dr. Wang holds a bachelor’s degree from Queen’s University (Kingston, ON) and a Ph.D from the University at Albany.